| For: | Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [PMID: 35611205 DOI: 10.12998/wjcc.v10.i11.3321] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i11/3321.htm |
| Number | Citing Articles |
| 1 |
Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews 2025; 141: 103046 doi: 10.1016/j.ctrv.2025.103046
|
| 2 |
Min Yao, Ping Zhou, Yan-Yan Qin, Li Wang, Deng-Fu Yao. Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis. World Journal of Gastroenterology 2023; 29(12): 1765-1778 doi: 10.3748/wjg.v29.i12.1765
|
| 3 |
Min Yao, Rong-Fei Fang, Qun Xie, Min Xu, Wen-Li Sai, Deng-Fu Yao. Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(6): 2350-2361 doi: 10.4251/wjgo.v16.i6.2350
|
| 4 |
Qing Li, Tianyi Wang, Ximin Wang, XinYu Ge, Tao Yang, Wei Wang. DDX56 promotes EMT and cancer stemness via MELK-FOXM1 axis in hepatocellular carcinoma. iScience 2024; 27(6): 109827 doi: 10.1016/j.isci.2024.109827
|
